CDH1 and breast carcinoma: The results showed that the level of membrane-bound E-cadherin was increased after the treatment of ilimaquinone, while the level of nuclear β-catenin was decreased (Figure S1), supporting the notion that ilimaquinone inhibited cell proliferation in breast cancer cells.